CERo Therapeutics Adds UC Davis as Site for Phase 1 CER-1236 Trial in Blood Cancers

• CERo Therapeutics activated UC Davis as a site for its ongoing Phase 1 CERTAIN-T trial of CER-1236 in blood cancers.
• UC Davis also manufactures CER-1236, potentially expanding recruitment capacity while shortening the time between manufacturing and patient infusion.
• Previously reported findings covered six patients; a June 2026 update showed no severe treatment-related adverse events during the initial safety assessment.
• Preliminary observations indicated clinical improvement in two patients, but formal assessments remain ongoing; definitive safety or efficacy conclusions cannot yet be drawn.
• The trial protocol now includes myelodysplastic syndromes and myelofibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610261721PRIMZONEFULLFEED9853519) on October 26, 2026, and is solely responsible for the information contained therein.